FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804983248> ?p ?o ?g. }

• W2804983248 endingPage "3788" @default.
• W2804983248 startingPage "3779" @default.
• W2804983248 abstract "Injection using needle and syringe (N&S) is the most widely used method for vaccination, but requires trained healthcare workers. Fear of needles, risk of needle-stick injury, and the need to reconstitute lyophilised vaccines, are also drawbacks. The Nanopatch (NP) is a microarray skin patch comprised of a high-density array of microprojections dry-coated with vaccine that is being developed to address these shortcomings. Here we report a randomised, partly-blinded, placebo-controlled trial that represents the first use in humans of the NP to deliver a vaccine. Healthy volunteers were vaccinated once with one of the following: (1) NPs coated with split inactivated influenza virus (A/California/07/2009 [H1N1], 15 µg haemagglutinin (HA) per dose), applied to the volar forearm (NP-HA/FA), n = 15; (2) NPs coated with split inactivated influenza virus (A/California/07/2009 [H1N1], 15 µg HA per dose), applied to the upper arm (NP-HA/UA), n = 15; (3) Fluvax® 2016 containing 15 µg of the same H1N1 HA antigen injected intramuscularly (IM) into the deltoid (IM-HA/D), n = 15; (4) NPs coated with excipients only, applied to the volar forearm (NP-placebo/FA), n = 5; (5) NPs coated with excipients only applied to the upper arm (NP-placebo/UA), n = 5; or (6) Saline injected IM into the deltoid (IM-placebo/D), n = 5. Antibody responses at days 0, 7, and 21 were measured by haemagglutination inhibition (HAI) and microneutralisation (MN) assays. NP vaccination was safe and acceptable; all adverse events were mild or moderate. Most subjects (55%) receiving patch vaccinations (HA or placebo) preferred the NP compared with their past experience of IM injection with N&S (preferred by 24%). The antigen-vaccinated groups had statistically higher HAI titres at day 7 and 21 compared with baseline (p < 0.0001), with no statistical differences between the treatment groups (p > 0.05), although the group sizes were small. The geometric mean HAI titres at day 21 for the NP-HA/FA, NP-HA/UA and IM-HA/D groups were: 335 (189–593 95% CI), 160 (74–345 95% CI), and 221 (129–380 95% CI) respectively. A similar pattern of responses was seen with the MN assays. Application site reactions were mild or moderate, and more marked with the influenza vaccine NPs than with the placebo or IM injection. Influenza vaccination using the NP appeared to be safe, and acceptable in this first time in humans study, and induced similar immune responses to vaccination by IM injection." @default.
• W2804983248 created "2018-06-01" @default.
• W2804983248 creator A5015270214 @default.
• W2804983248 creator A5020854521 @default.
• W2804983248 creator A5022414876 @default.
• W2804983248 creator A5025732042 @default.
• W2804983248 creator A5042701655 @default.
• W2804983248 creator A5045348624 @default.
• W2804983248 creator A5048082417 @default.
• W2804983248 creator A5061693918 @default.
• W2804983248 creator A5064780677 @default.
• W2804983248 creator A5065777873 @default.
• W2804983248 creator A5081371818 @default.
• W2804983248 creator A5086563558 @default.
• W2804983248 creator A5087674280 @default.
• W2804983248 date "2018-06-01" @default.
• W2804983248 modified "2023-10-16" @default.
• W2804983248 title "Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™)" @default.
• W2804983248 cites W1960083897 @default.
• W2804983248 cites W1967548018 @default.
• W2804983248 cites W1971863415 @default.
• W2804983248 cites W1974028549 @default.
• W2804983248 cites W1976076274 @default.
• W2804983248 cites W2003818435 @default.
• W2804983248 cites W2014506882 @default.
• W2804983248 cites W2022065543 @default.
• W2804983248 cites W2036937828 @default.
• W2804983248 cites W2041913794 @default.
• W2804983248 cites W2088368520 @default.
• W2804983248 cites W2093692060 @default.
• W2804983248 cites W2103742770 @default.
• W2804983248 cites W2118257082 @default.
• W2804983248 cites W2151167522 @default.
• W2804983248 cites W2233945743 @default.
• W2804983248 cites W2293145130 @default.
• W2804983248 cites W2326904022 @default.
• W2804983248 cites W2462886429 @default.
• W2804983248 cites W2473536856 @default.
• W2804983248 cites W2592692387 @default.
• W2804983248 cites W2605322593 @default.
• W2804983248 cites W2732601320 @default.
• W2804983248 cites W2765559122 @default.
• W2804983248 cites W4250928742 @default.
• W2804983248 doi "https://doi.org/10.1016/j.vaccine.2018.05.053" @default.
• W2804983248 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29779922" @default.
• W2804983248 hasPublicationYear "2018" @default.
• W2804983248 type Work @default.
• W2804983248 sameAs 2804983248 @default.
• W2804983248 citedByCount "84" @default.
• W2804983248 countsByYear W28049832482018 @default.
• W2804983248 countsByYear W28049832482019 @default.
• W2804983248 countsByYear W28049832482020 @default.
• W2804983248 countsByYear W28049832482021 @default.
• W2804983248 countsByYear W28049832482022 @default.
• W2804983248 countsByYear W28049832482023 @default.
• W2804983248 crossrefType "journal-article" @default.
• W2804983248 hasAuthorship W2804983248A5015270214 @default.
• W2804983248 hasAuthorship W2804983248A5020854521 @default.
• W2804983248 hasAuthorship W2804983248A5022414876 @default.
• W2804983248 hasAuthorship W2804983248A5025732042 @default.
• W2804983248 hasAuthorship W2804983248A5042701655 @default.
• W2804983248 hasAuthorship W2804983248A5045348624 @default.
• W2804983248 hasAuthorship W2804983248A5048082417 @default.
• W2804983248 hasAuthorship W2804983248A5061693918 @default.
• W2804983248 hasAuthorship W2804983248A5064780677 @default.
• W2804983248 hasAuthorship W2804983248A5065777873 @default.
• W2804983248 hasAuthorship W2804983248A5081371818 @default.
• W2804983248 hasAuthorship W2804983248A5086563558 @default.
• W2804983248 hasAuthorship W2804983248A5087674280 @default.
• W2804983248 hasBestOaLocation W28049832481 @default.
• W2804983248 hasConcept C118552586 @default.
• W2804983248 hasConcept C126322002 @default.
• W2804983248 hasConcept C141071460 @default.
• W2804983248 hasConcept C142724271 @default.
• W2804983248 hasConcept C147483822 @default.
• W2804983248 hasConcept C159047783 @default.
• W2804983248 hasConcept C182072434 @default.
• W2804983248 hasConcept C197934379 @default.
• W2804983248 hasConcept C203014093 @default.
• W2804983248 hasConcept C204787440 @default.
• W2804983248 hasConcept C22070199 @default.
• W2804983248 hasConcept C2522874641 @default.
• W2804983248 hasConcept C27081682 @default.
• W2804983248 hasConcept C2777397205 @default.
• W2804983248 hasConcept C2778375690 @default.
• W2804983248 hasConcept C2778571141 @default.
• W2804983248 hasConcept C2780689484 @default.
• W2804983248 hasConcept C2780868878 @default.
• W2804983248 hasConcept C32611913 @default.
• W2804983248 hasConcept C71924100 @default.
• W2804983248 hasConceptScore W2804983248C118552586 @default.
• W2804983248 hasConceptScore W2804983248C126322002 @default.
• W2804983248 hasConceptScore W2804983248C141071460 @default.
• W2804983248 hasConceptScore W2804983248C142724271 @default.
• W2804983248 hasConceptScore W2804983248C147483822 @default.
• W2804983248 hasConceptScore W2804983248C159047783 @default.
• W2804983248 hasConceptScore W2804983248C182072434 @default.
• W2804983248 hasConceptScore W2804983248C197934379 @default.

• next